ALLO-316 shows promising results in advanced renal cell carcinoma, with a 25% response rate and rapid treatment turnaround, ...

Researchers identify PPP2R1A gene mutations as a new marker linked to better immunotherapy response and survival in ovarian ...

The anti-GPC3 targeted therapies market is expected to witness growth in the coming years, driven by the increasing incidence of cancer cases, clinical pipeline activity, and anticipated regulatory ...

("LIXTE” or the "Company”) (Nasdaq: LIXT and LIXTW), a clinical stage pharmaceutical company, today announced that the ...

Manojkumar Bupathi, MD, MS, discusses physician perspectives on treatment selection for frontline metastatic renal cell carcinoma (RCC) from a Case-Based Roundtable event.

In light of the above, this morning Bell Potter has reaffirmed its buy rating and $34.00 price target on the ...

But skin cancer can also develop in areas that aren’t regularly exposed to the sun, including the palms of the hands, soles ...

After sharing her breast cancer diagnosis in 2024, Olivia Munn shared that her mother Kim Munn went through her own battle ...

New York, NY, July 09, 2025 (GLOBE NEWSWIRE) -- Spartan Capital Securities, LLC, a premier investment banking firm, is pleased to announce the closing of a $1.5 million registered direct offering for ...

Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced ...

Lixte Biotechnology Holdings, Inc. (NASDAQ: LIXT) (the 'Company”), a clinical stage pharmaceutical company, today announced ...

SCG Cell Therapy Pte Ltd (SCG), a clinical-stage biotechnology company pioneering TCR T cell therapy for infectious diseases and associated cancers, announced today that the China National Medical ...